Search

Your search keyword '"Delforge, Michel"' showing total 1,139 results
Start Over Author "Delforge, Michel"
1,139 results on '"Delforge, Michel"'

153. Additional file 1 of Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Author

Tremblay, Gabriel, Daniele, Patrick, Breeze, Janis, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Engelhardt, Monika, Chari, Ajaj, Nooka, Ajay, Vogl, Dan, Gavriatopoulou, Maria, Dimopoulos, Meletios-Athanasios, Richardson, Paul, Biran, Noa, Siegel, David, Vlummens, Philip, Doyen, Chantal, Facon, Thierry, Mohty, Mohamad, Meuleman, Nathalie, Levy, Moshe, Costa, Luciano, Hoffman, James E., Delforge, Michel, Kaminetzky, David, Weisel, Katja, Raab, Marc, Dingli, David, Tuchman, Sascha, Laurent, Frenzel, Vij, Ravi, Schiller, Gary, Moreau, Philippe, Richter, Joshua, Schreder, Martin, Podar, Klaus, Parker, Terri, Cornell, Robert Frank, Lionel, Karlin, Choquet, Sylvain, and Sundar, Jagannath

Abstract

Additional file 1 Table 1. Patients with improvement, no change, or decline in HRQoL based on minimal clinically important differences defined by ≥ 10% of the instrument range. Table 1 describes the number and proportion of patients with improvement, no change, or decline in HRQoL based on the minimal clinically important difference threshold defined as ≥10% of the instrument range. Data are shown for the FACT-MM, FACT-G, FACT-MM TOI, and the MM domain at treatment cycle 2–6 and end of treatment.

Published
2021
Full Text
View/download PDF

154. Additional file 2 of Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Author

Tremblay, Gabriel, Daniele, Patrick, Breeze, Janis, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Engelhardt, Monika, Chari, Ajaj, Nooka, Ajay, Vogl, Dan, Gavriatopoulou, Maria, Dimopoulos, Meletios-Athanasios, Richardson, Paul, Biran, Noa, Siegel, David, Vlummens, Philip, Doyen, Chantal, Facon, Thierry, Mohty, Mohamad, Meuleman, Nathalie, Levy, Moshe, Costa, Luciano, Hoffman, James E., Delforge, Michel, Kaminetzky, David, Weisel, Katja, Raab, Marc, Dingli, David, Tuchman, Sascha, Laurent, Frenzel, Vij, Ravi, Schiller, Gary, Moreau, Philippe, Richter, Joshua, Schreder, Martin, Podar, Klaus, Parker, Terri, Cornell, Robert Frank, Lionel, Karlin, Choquet, Sylvain, and Sundar, Jagannath

Abstract

Additional file 2. Provides a list of IECs and IRBs for the STORM trial.

Published
2021
Full Text
View/download PDF

155. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Author

Tremblay, Gabriel Daniele, Patrick Breeze, Janis Li, Lingling Shah, Jatin Shacham, Sharon Kauffman, Michael and Engelhardt, Monika Chari, Ajaj Nooka, Ajay Vogl, Dan and Gavriatopoulou, Maria Dimopoulos, Meletios-Athanasios and Richardson, Paul Biran, Noa Siegel, David Vlummens, Philip and Doyen, Chantal Facon, Thierry Mohty, Mohamad Meuleman, Nathalie Levy, Moshe Costa, Luciano Hoffman, James E. and Delforge, Michel Kaminetzky, David Weisel, Katja Raab, Marc and Dingli, David Tuchman, Sascha Laurent, Frenzel Vij, Ravi and Schiller, Gary Moreau, Philippe Richter, Joshua and Schreder, Martin Podar, Klaus Parker, Terri Cornell, Robert Frank Lionel, Karlin Choquet, Sylvain Sundar, Jagannath

Abstract

Background: Selinexor is an oral, selective nuclear export inhibitor. STORM was a phase 2b, single-arm, open-label, multicenter trial of selinexor with low dose dexamethasone in patients with penta-exposed relapsed/refractory multiple myeloma (RRMM) that met its primary endpoint, with overall response of 26% (95% confidence interval [CI], 19 to 35%). Health-related quality of life (HRQoL) was a secondary endpoint measured using the Functional Assessment of Cancer Therapy - Multiple Myeloma (FACT-MM). This study examines impact of selinexor treatment on HRQoL of patients treated in STORM and reports two approaches to calculate minimal clinically important differences for the FACT-MM. Methods: FACT-MM data were collected at baseline, on day 1 of each 4-week treatment cycle, and at end of treatment (EOT). Changes from baseline were analyzed for the FACT-MM total score, FACT-trial outcome index (TOI), FACT-General (FACT-G), and the MM-specific domain using mixed-effects regression models. Two approaches for evaluating minimal clinically important differences were explored: the first defined as 10% of the instrument range, and the second based on estimated mean baseline differences between Eastern Cooperative Oncology Group performance status (ECOG PS) scores. Post-hoc difference analysis compared change in scores from baseline to EOT for treatment responders and non-responders. Results: Eighty patients were included in the analysis; the mean number of prior therapies was 7.9 (standard deviation [SD] 3.1), and mean duration of myeloma was 7.6 years (SD 3.4). Each exploratory minimal clinically important difference threshold yielded consistent results whereby most patients did not experience HRQoL decline during the first six cycles of treatment (range: 53.9 to 75.7% for the first approach; range: 52.6 to 72.9% for the second). Treatment responders experienced less decline in HRQoL from baseline to EOT than non-responders, which was significant for the FACT-G, but not for other scores. Conclusion: The majority of patients did not experience decline in HRQoL based on minimal clinically important differences during early cycles of treatment with selinexor and dexamethasone in the STORM trial. An anchor-based approach utilizing patient-level data (ECOG PS score) to define minimal clinically important differences for the FACT-MM gave consistent results with a distribution-based approach.

Published
2021

157. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

Author

Ludwig, Heinz Sonneveld, Pieter Facon, Thierry San-Miguel, Jesus Avet-Loiseau, Herve Mohty, Mohamad Mateos, Maria-Victoria Moreau, Philippe Cavo, Michele Pawlyn, Charlotte Zweegman, Sonja Engelhardt, Monika Driessen, Christoph Cook, Gordon Dimopoulos, Melitios A. Gay, Francesca Einsele, Hermann Delforge, Michel Caers, Jo and Weisel, Katja Jackson, Graham Garderet, Laurent van de Donk, Niels Leleu, Xavier Goldschmidt, Hartmut Beksac, Meral and Nijhof, Inger Schreder, Martin Abildgaard, Niels Hajek, Roman Zojer, Niklas Kastritis, Efstathios Broijl, Annemiek and Schjesvold, Fredrik Boccadoro, Mario Terpos, Evangelos

Abstract

Patients with multiple myeloma frequently present with substantial immune impairment and an increased risk for infections and infection-related mortality. The risk for infection with SARS-CoV-2 virus and resulting mortality is also increased, emphasising the importance of protecting patients by vaccination. Available data in patients with multiple myeloma suggest a suboptimal anti-SARS-CoV-2 immune response, meaning a proportion of patients are unprotected. Factors associated with poor response are uncontrolled disease, immunosuppression, concomitant therapy, more lines of therapy, and CD38 antibody-directed and B-cell maturation antigen-directed therapy. These facts suggest that monitoring the immune response to vaccination in patients with multiple myeloma might provide guidance for clinical management, such as administration of additional doses of the same or another vaccine, or even temporary treatment discontinuation, if possible. In those who do not exhibit a good response, prophylactic treatment with neutralising monoclonal antibody cocktails might be considered. In patients deficient of a SARS-CoV-2 immune response, adherence to measures for infection risk reduction is particularly recommended. This consensus was generated by members of the European Multiple Myeloma Network and some external experts. The panel members convened in virtual meetings and conducted an extensive literature research and evaluated recently published data and work presented at meetings, as well as findings from their own studies. The outcome of the discussions on establishing consensus recommendations for COVID-19 vaccination in patients with multiple myeloma was condensed into this Review.

Published
2021

159. CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

Author

Agha, Mounzer E., primary, Cohen, Adam D., additional, Madduri, Deepu, additional, Cohen, Yael C., additional, Delforge, Michel, additional, Hillengass, Jens, additional, Goldschmidt, Hartmut, additional, Weisel, Katja, additional, Raab, Marc-Steffen, additional, Scheid, Christof, additional, Schecter, Jordan Mark, additional, De Braganca, Kevin C., additional, Varsos, Helen, additional, Wang, Liwei, additional, Vogel, Martin, additional, Carrasco-Alfonso, Marlene, additional, Akram, Muhammad, additional, Wu, Xiaoling, additional, Nesheiwat, Tonia, additional, and Einsele, Hermann, additional

Published
2021
Full Text
View/download PDF

160. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma

Author

Rodriguez-Otero, Paula, primary, Ayers, Dieter, additional, Cope, Shannon, additional, Davies, Faith E., additional, Delforge, Michel, additional, Mojebi, Ali, additional, Jansen, Jeroen P., additional, Weisel, Katja, additional, Hege, Kristen, additional, and Dhanasiri, Sujith, additional

Published
2021
Full Text
View/download PDF

161. P-294 Comparative effectiveness of teclistamab vs real-world physician's choice of therapy in the LocoMMotion and MoMMent studies for patients with triple-class exposed relapsed/refractory multiple myeloma

Author

Mateos, Maria-Victoria, van de Donk, Niels, Delforge, Michel, Einsele, Hermann, De Stefano, Valerio, Lindsey-Hill, Joanne, Vincent, Laure, Kirkpatrick, Suriya, Besemer, Britta, Garcia, Maria Esther Gonzalez, Karlin, Lionel, Ghilotti, Francesca, Diels, Joris, Morano, Raúl, Albrecht, Claire, Strulev, Vadim, Haddad, Imène, Pei, Lixia, Kobos, Rachel, Smit, Jennifer, Slavcev, Mary, Marshall, Alexander, Weisel, Katja, and Moreau, Philippe

Published
2023
Full Text
View/download PDF

165. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Author

Benboubker, Lotfi, Dimopoulos, Meletios A., Dispenzieri, Angela, Catalano, John, Belch, Andrew R., Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, de la Rubia, Javier, Qiu, Lugui, White, Darrell J., Binder, Daniel, Anderson, Kenneth, Fermand, Jean-Paul, Moreau, Philippe, Attal, Michel, Knight, Robert, Chen, Guang, Van Oostendorp, Jason, Jacques, Christian, Ervin-Haynes, Annette, Avet-Loiseau, Hervé, Hulin, Cyrille, and Facon, Thierry

Published
2014
Full Text
View/download PDF

170. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Author

Munshi, Nikhil C., primary, Anderson, Larry D., additional, Shah, Nina, additional, Madduri, Deepu, additional, Berdeja, Jesús, additional, Lonial, Sagar, additional, Raje, Noopur, additional, Lin, Yi, additional, Siegel, David, additional, Oriol, Albert, additional, Moreau, Philippe, additional, Yakoub-Agha, Ibrahim, additional, Delforge, Michel, additional, Cavo, Michele, additional, Einsele, Hermann, additional, Goldschmidt, Hartmut, additional, Weisel, Katja, additional, Rambaldi, Alessandro, additional, Reece, Donna, additional, Petrocca, Fabio, additional, Massaro, Monica, additional, Connarn, Jamie N., additional, Kaiser, Shari, additional, Patel, Payal, additional, Huang, Liping, additional, Campbell, Timothy B., additional, Hege, Kristen, additional, and San-Miguel, Jesús, additional

Published
2021
Full Text
View/download PDF

172. Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Author

Moreau, Philippe, van de Donk, Niels W. C. J., Miguel, Jesus San, Lokhorst, Henk, Nahi, Hareth, Ben-Yehuda, Dina, Cavo, Michele, Cook, Gordon, Delforge, Michel, Einsele, Hermann, Zweegman, Sonja, Ludwig, Heinz, Driessen, Christoph, Palumbo, Antonio, Facon, Thierry, Plesner, Torben, Dimopoulos, Meletios, Sondergeld, Pia, Sonneveld, Pieter, and Mateos, María-Victoria

Published
2016
Full Text
View/download PDF

174. Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial

Author

Shah, Nina, primary, Delforge, Michel, additional, San-Miguel, Jesús F., additional, Bertin, Kaitlyn B., additional, Tahir, Muna J, additional, Lewis, Hannah B., additional, Wang, Julie, additional, Braverman, Julia, additional, Campbell, Timothy B., additional, Dhanda, Devender, additional, and Munshi, Nikhil C., additional

Published
2020
Full Text
View/download PDF

175. Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the Karmma Trial

Author

Delforge, Michel, primary, Shah, Nina, additional, Rodriguez-Otero, Paula, additional, Hari, Parameswaran, additional, Braverman, Julia, additional, Trigg, Andrew, additional, Patel, Payal, additional, Huang, Liping, additional, Hege, Kristen, additional, and Dhanasiri, Sujith, additional

Published
2020
Full Text
View/download PDF

176. KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma

Author

Delforge, Michel, primary, Baz, Rachid C., additional, Cavo, Michele, additional, Callander, Natalie S., additional, Ghobadi, Armin, additional, Rodriguez-Otero, Paula, additional, Mateos, María-Victoria, additional, Massaro, Monica, additional, Ding, Li, additional, Patel, Payal, additional, Pittari, Gianfranco, additional, Novick, Steven, additional, Giralt, Sergio A., additional, and Berdeja, Jesus G., additional

Published
2020
Full Text
View/download PDF

180. Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

Author

Palumbo, Antonio, Hajek, Roman, Delforge, Michel, Kropff, Martin, Petrucci, Maria Teresa, Catalano, John, Gisslinger, Heinz, Wiktor-Jędrzejczak, Wiesław, Zodelava, Mamia, Weisel, Katja, Cascavilla, Nicola, Iosava, Genadi, Cavo, Michele, Kloczko, Janusz, Bladé, Joan, Beksac, Meral, Spicka, Ivan, Plesner, Torben, Radke, Joergen, Langer, Christian, Yehuda, Dina Ben, Corso, Alessandro, Herbein, Lindsay, Yu, Zhinuan, Mei, Jay, Jacques, Christian, and Dimopoulos, Meletios A.

Published
2012
Full Text
View/download PDF

181. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

Author

Delforge, Michel, Terpos, Evangelos, Richardson, Paul G., Shpilberg, Ofer, Khuageva, Nuriet K., Schlag, Rudolf, Dimopoulos, Meletios A., Kropff, Martin, Spicka, Ivan, Petrucci, Maria T., Samoilova, Olga S., Mateos, Maria-Victoria, Magen-Nativ, Hila, Goldschmidt, Hartmut, Esseltine, Dixie-Lee, Ricci, Deborah S., Liu, Kevin, Deraedt, William, Cakana, Andrew, van de Velde, Helgi, and San Miguel, Jesús F.

Published
2011
Full Text
View/download PDF

182. A double-edged sword

Author

Vandebotermet, Martijn, primary, Staels, Frederik, additional, Giovannozzi, Simone, additional, Delforge, Michel, additional, Tousseyn, Thomas, additional, Steelandt, Thomas, additional, Corveleyn, Anniek, additional, Meyts, Isabelle, additional, Maertens, Johan, additional, Yserbyt, Jonas, additional, and Schrijvers, Rik, additional

Published
2020
Full Text
View/download PDF

183. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Author

Ludwig, Heinz, primary, Boccadoro, Mario, additional, Moreau, Philippe, additional, San-Miguel, Jesus, additional, Cavo, Michele, additional, Pawlyn, Charlotte, additional, Zweegman, Sonja, additional, Facon, Thierry, additional, Driessen, Christoph, additional, Hajek, Roman, additional, Dimopoulos, Melitios A., additional, Gay, Francesca, additional, Avet-Loiseau, Hervé, additional, Terpos, Evangelos, additional, Zojer, Niklas, additional, Mohty, Mohamad, additional, Mateos, Maria-Victoria, additional, Einsele, Hermann, additional, Delforge, Michel, additional, Caers, Jo, additional, Weisel, Katja, additional, Jackson, Graham, additional, Garderet, Laurent, additional, Engelhardt, Monika, additional, van de Donk, Niels, additional, Leleu, Xavier, additional, Goldschmidt, Hartmut, additional, Beksac, Meral, additional, Nijhof, Inger, additional, Abildgaard, Niels, additional, Bringhen, Sara, additional, and Sonneveld, Pieter, additional

Published
2020
Full Text
View/download PDF

184. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT

Author

Gagelmann, Nico, primary, Eikema, Diderik-Jan, additional, de Wreede, Liesbeth C., additional, Rambaldi, Alessandro, additional, Iacobelli, Simona, additional, Koster, Linda, additional, Caillot, Denis, additional, Blaise, Didier, additional, Remémyi, Péter, additional, Bulabois, Claude-Eric, additional, Passweg, Jakob, additional, Leleu, Xavier, additional, Zver, Samo, additional, Kobbe, Guido, additional, Ljungman, Per, additional, Chevallier, Patrice, additional, Ringhoffer, Mark, additional, Martin, Murray, additional, Salmenniemi, Urpu, additional, Poiré, Xavier, additional, Lenhoff, Stig, additional, Pioltelli, Pietro, additional, Mordini, Nicola, additional, Delforge, Michel, additional, Garderet, Laurent, additional, Schönland, Stefan, additional, Yakoub-Agha, Ibrahim, additional, and Kröger, Nicolaus, additional

Published
2020
Full Text
View/download PDF

185. Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1

Author

Fitzgibbon, Jude, primary, Park, Sophie, additional, Cook, Gordon, additional, Paiva, Bruno, additional, Gloghini, Annunziata, additional, Van Breda, Eric, additional, Busti, Fabiana, additional, Garderet, Laurent, additional, Dolcetti, Ricardo, additional, Robin, Marie, additional, Martino, Rodrigo, additional, Busca, Alessandro, additional, Sabbah, Michèle, additional, De Rosa, Salvatore, additional, Martini, Maurizio, additional, Onida, Francesco, additional, Aucouturier, Pierre, additional, Schjesvold, Fredrik, additional, Minvielle, Stéphane, additional, Mazzucato, Mario, additional, Terragna, Carolina, additional, Delforge, Michel, additional, Harrison, Claire, additional, and Carbone, Antonino, additional

Published
2020
Full Text
View/download PDF

187. COVID-19, impact on myeloma patients

Author

Dufour, Inès, primary, Raedemaeker, Juliette, additional, Andreozzi, Fabio, additional, Verstraete, Géraldine, additional, Bailly, Sarah, additional, Delforge, Michel, additional, Storms, Pauline, additional, Jacquy, Caroline, additional, Van de Velde, Ann, additional, Mineur, Philippe, additional, Lejeune, Marie, additional, Bauwens, Deborah, additional, Van Obbergh, Florence, additional, Kentos, Alain, additional, Nguyen, Jasmine, additional, Fostier, Karel, additional, De Weweire, Anne, additional, Meuleman, Nathalie, additional, and Vekemans, Marie-Christiane, additional

Published
2020
Full Text
View/download PDF

188. Ultra‐low depth sequencing of plasma cell DNA for the detection of copy number aberrations in multiple myeloma

Author

Buedts, Lieselot, primary, Smits, Sanne, additional, Ameye, Geneviève, additional, Lehnert, Stefan, additional, Ding, Jia, additional, Delforge, Michel, additional, Vermeesch, Joris, additional, Boeckx, Nancy, additional, Tousseyn, Thomas, additional, Michaux, Lucienne, additional, Vandenberghe, Peter, additional, and Dewaele, Barbara, additional

Published
2020
Full Text
View/download PDF

190. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

Author

Goldman-Mazur, Sarah, primary, Jurczyszyn, Artur, additional, Castillo, Jorge J., additional, Waszczuk-Gajda, Anna, additional, Grząśko, Norbert, additional, Radocha, Jakub, additional, Bittrich, Max, additional, Kortüm, Klaus Martin, additional, Gozzetti, Alessandro, additional, Usnarska-Zubkiewicz, Lidia, additional, Valls, Julio D., additional, Jayabalan, David S., additional, Niesvizky, Ruben, additional, Kelman, Julia, additional, Coriu, Daniel, additional, Rosiñol, Laura, additional, Szukalski, Łukasz, additional, González-Calle, Veronica, additional, Mateos, María-Victoria, additional, Jamroziak, Krzysztof, additional, Hus, Iwona, additional, Avivi, Irit, additional, Cohen, Yael, additional, Mazur, Piotr, additional, Suska, Anna, additional, Chappell, Aimee, additional, Madduri, Deepu, additional, Chhabra, Saurabh, additional, Kleman, Ariel, additional, Hari, Parameswaran, additional, Delforge, Michel, additional, Robak, Paweł, additional, Gentile, Massimo, additional, Kozłowska, Izabela, additional, Goldberg, Stuart L., additional, Czepiel, Jacek, additional, Długosz-Danecka, Monika, additional, Silbermann, Rebecca, additional, Olszewski, Adam J., additional, Barth, Peter, additional, Mikala, Gabor, additional, Chim, Chor S., additional, and Vesole, David H., additional

Published
2020
Full Text
View/download PDF

191. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

Author

Goldman‐Mazur, Sarah, primary, Jurczyszyn, Artur, additional, Castillo, Jorge J., additional, Waszczuk‐Gajda, Anna, additional, Grząśko, Norbert, additional, Radocha, Jakub, additional, Bittrich, Max, additional, Kortüm, K. Martin, additional, Gozzetti, Alessandro, additional, Usnarska‐Zubkiewicz, Lidia, additional, Davila Valls, Julio, additional, Jayabalan, David S., additional, Niesvizky, Ruben, additional, Kelman, Julia, additional, Coriu, Daniel, additional, Rosiñol, Laura, additional, Szukalski, Łukasz, additional, González‐Calle, Veronica, additional, Mateos, Maria V., additional, Jamroziak, Krzysztof, additional, Hus, Iwona, additional, Avivi, Irit, additional, Cohen, Yael, additional, Suska, Anna, additional, Chappell, Aimee, additional, Madduri, Deepu, additional, Chhabra, Saurabh, additional, Kleman, Ariel, additional, Hari, Parameswaran, additional, Delforge, Michel, additional, Robak, Paweł, additional, Gentile, Massimo, additional, Kozłowska, Izabela, additional, Goldberg, Stuart L., additional, Czepiel, Jacek, additional, Silbermann, Rebecca, additional, Olszewski, Adam J., additional, Barth, Peter, additional, Mikala, Gabor, additional, Chim, Chor S., additional, Długosz‐Danecka, Monika, additional, Grosicki, Sebastian, additional, and Vesole, David H., additional

Published
2020
Full Text
View/download PDF

194. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Author

Attal, Michel, primary, Richardson, Paul G, additional, Rajkumar, S Vincent, additional, San-Miguel, Jesus, additional, Beksac, Meral, additional, Spicka, Ivan, additional, Leleu, Xavier, additional, Schjesvold, Fredrik, additional, Moreau, Philippe, additional, Dimopoulos, Meletios A, additional, Huang, Jeffrey Shang-Yi, additional, Minarik, Jiri, additional, Cavo, Michele, additional, Prince, H Miles, additional, Macé, Sandrine, additional, Corzo, Kathryn P, additional, Campana, Frank, additional, Le-Guennec, Solenn, additional, Dubin, Franck, additional, Anderson, Kenneth C, additional, Attal, Michel, additional, Richardson, Paul G., additional, Rajkumar, Vincent, additional, Dimopoulos, Meletios A., additional, Prince, H. Miles, additional, Corzo, Kathryn P., additional, Anderson, Kenneth C., additional, Harrison, Simon, additional, Janowski, Wojt, additional, Kerridge, Ian, additional, Spencer, Andrew, additional, Delforge, Michel, additional, Fostier, Karel, additional, Vlummens, Philip, additional, Wu, Ka Lung, additional, Leblanc, Richard, additional, Pavic, Michel, additional, Sebag, Michael, additional, Hajek, Roman, additional, Maisnar, Vladimir, additional, Pour, Ludek, additional, Gregersen, Henrik, additional, Benbouker, Lotfi, additional, Caillot, Denis, additional, Escoffre-Barbe, Martine, additional, Facon, Thierry, additional, Frenzel, Laurent, additional, Hulin, Cyrille, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Pegourie, Brigitte, additional, Perrot, Aurore, additional, Tiab, Mourad, additional, Vincent, Laure, additional, Niederwieser, Dietger, additional, Anagnostopoulos, Achilles, additional, Delimpasi, Sosana, additional, Kyrtsonis, Marie-Christine, additional, Symeonidis, Anargyros, additional, Illes, Arpad, additional, Mikala, Gabor, additional, Nagy, Zsolt, additional, Bringen, Sara, additional, Corradini, Paolo, additional, Fabio, Ciceri, additional, Lemoli, Roberto, additional, Liberati, Anna, additional, Nozzoli, Chiara, additional, Zambello, Renato, additional, Iida, Shinsuke, additional, Ikeda, Takashi, additional, Iyama, Satoshi, additional, Matsumoto, Morio, additional, Shimazaki, Chihiro, additional, Sunami, Kazutaka, additional, Suzuki, Kenshi, additional, Uchiyama, Michihiro, additional, Koh, Youngil, additional, Kim, Kihyun, additional, Lee, Jae Hoon, additional, Min, Chang-Ki, additional, Blacklock, Hillary, additional, Goodman, Hugh, additional, Neylon, Annette, additional, Simpson, David, additional, Grosicki, Sebastian, additional, Jurczyszyn, Artur, additional, Walter-Croneck, Adam, additional, Warzocha, Krzysztof, additional, Araujo, Luis, additional, Moreira, Claudia, additional, Doronin, Vadim, additional, Mendeleeva, Larisa, additional, Vorobyev, Vladimir, additional, Vranovsky, Andrej, additional, Alegre, Adrian, additional, Gironella, Mercedes, additional, Gonzalez Perez, Marta Sonia, additional, Montes, Carmen, additional, Ocio, Enrique, additional, Rodriguez, Paula, additional, Hardling, Mats, additional, Lauri, Birgitta, additional, Wang, Ming-Chung, additional, Yeh, Su-Peng, additional, Arat, Mutlu, additional, Demirkan, Fatih, additional, Gulbas, Zafer, additional, Besisik, Sevgi Kalayoglu, additional, Karadogan, Ihsan, additional, Tuglular, Tulin, additional, Unal, Ali, additional, Vural, Filiz, additional, Sive, Jonathan, additional, Streetly, Matthew, additional, Yong, Kwee, additional, and Tache, Jason, additional

Published
2019
Full Text
View/download PDF

195. Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial

Author

Manier, Salmon, primary, Dimopoulos, Meletios A., additional, Hulin, Cyrille, additional, Leleu, Xavier, additional, Delforge, Michel, additional, Weisel, Katja C., additional, Jiang, Ruiyun, additional, Srinivasan, Shankar, additional, Costa, Bruno, additional, Robinson, Suzanne, additional, and Facon, Thierry, additional

Published
2019
Full Text
View/download PDF

196. The Locommotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression

Author

Delforge, Michel, primary, Moreau, Philippe, additional, Mateos, Maria-Victoria, additional, De Stefano, Valerio, additional, Weisel, Katja, additional, San-Miguel, Jesús, additional, Einsele, Hermann, additional, Facon, Thierry, additional, Boccadoro, Mario, additional, Goldschmidt, Hartmut, additional, Cavo, Michele, additional, Rosinol, Laura, additional, Kaiser, Martin F., additional, Gay, Francesca, additional, Scheid, Christof, additional, Broyl, Annemiek, additional, Van De Donk, Niels W. C. J., additional, Rodriguez, Paula, additional, Potamianou, Anna, additional, Sakabedoyan, Caline, additional, Strulev, Vadim, additional, Nesheiwat, Tonia, additional, Bergmans, Paul, additional, Rizvi, Syed, additional, Pilatowicz, Arkadiusz, additional, and Sonneveld, Pieter, additional

Published
2019
Full Text
View/download PDF

198. Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant

Author

Gries, Katharine, primary, Facon, Thierry, additional, Plesner, Torben, additional, Usmani, Saad, additional, Kumar, Shaji, additional, Orlowski, Robert Z., additional, Bahlis, Nizar J., additional, Nahi, Hareth, additional, Mollee, Peter, additional, Ramasamy, Karthik, additional, ROUSSEL, Murielle, additional, Delforge, Michel, additional, KARLIN, Lionel, additional, Arnulf, Bertrand, additional, Chari, Ajai, additional, HULIN, Cyrille, additional, Weisel, Katja, additional, He, Jianming, additional, Ho, Kai Fai, additional, Wang, Jim, additional, Van Rampelbergh, Rian, additional, Uhlar, Clarissa, additional, kobos, rachel, additional, and Perrot, Aurore, additional

Published
2019
Full Text
View/download PDF

199. Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA

Author

Sonneveld, Pieter, primary, Attal, Michel, additional, Perrot, Aurore, additional, Hulin, Cyrille, additional, Caillot, Denis, additional, Facon, Thierry, additional, Leleu, Xavier, additional, Belhadj-Merzoug, Karim, additional, Karlin, Lionel, additional, Benboubker, Lofti, additional, Levin, Mark-David, additional, Minnema, Monique, additional, Westerman, Matthijs, additional, Delforge, Michel, additional, Zweegman, Sonja, additional, Pei, Lixia, additional, de Boer, Carla, additional, Vanquickelberghe, Véronique, additional, Kampfenkel, Tobias, additional, and Moreau, Philippe, additional

Published
2019
Full Text
View/download PDF

200. Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA

Author

Avet-Loiseau, Herve, primary, Bene, Marie C., additional, Wuilleme, Soraya, additional, Corre, Jill, additional, Attal, Michel, additional, Arnulf, Bertrand, additional, Garderet, Laurent, additional, Macro, Margaret, additional, Stoppa, Anne-Marie, additional, Delforge, Michel, additional, Broijl, Annemiek, additional, Zweegman, Sonja, additional, Jie, Kon-Siong, additional, Van de Donk, Niels, additional, Pei, Lixia, additional, de Boer, Carla, additional, Chiu, Chris, additional, Vanquickelberghe, Véronique, additional, Kampfenkel, Tobias, additional, Vermeulen, Jessica, additional, Moreau, Philippe, additional, and Sonneveld, Pieter, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results